Comorbidities and COVID-19 hospitalization, ICU admission and hospital mortality in Austria

Abstract

Background The protection of vulnerable populations is a central task in managing the Coronavirus disease 2019 (COVID-19) pandemic to avoid severe courses of COVID-19 and the risk of healthcare system capacity being exceeded. To identify factors of vulnerability in Austria, we assessed the impact of comorbidities on COVID-19 hospitalization, intensive care unit (ICU) admission, and hospital mortality. Methods A retrospective cohort study was performed including all patients with COVID-19 in the period February 2020 to December 2021 who had a previous inpatient stay in the period 2015–2019 in Austria. All patients with COVID-19 were matched to population controls on age, sex, and healthcare region. Multiple logistic regression was used to estimate adjusted odds ratios (OR) of included factors with 95% confidence intervals (CI). Results Hemiplegia or paraplegia constitutes the highest risk factor for hospitalization (OR 1.61, 95% CI 1.44–1.79), followed by COPD (OR 1.48, 95% CI 1.43–1.53) and diabetes without complications (OR 1.41, 95% CI 1.37–1.46). The highest risk factors for ICU admission are renal diseases (OR 1.76, 95% CI 1.61–1.92), diabetes without complications (OR 1.57, 95% CI 1.46–1.69) and COPD (OR 1.53, 95% CI 1.41–1.66). Hemiplegia or paraplegia, renal disease and COPD constitute the highest risk factors for hospital mortality, with ORs of 1.5. Diabetes without complications constitutes a significantly higher risk factor for women with respect to all three endpoints. Conclusion We contribute to the literature by identifying sex-specific risk factors. In general, our results are consistent with the literature, particularly regarding diabetes as a risk factor for severe courses of COVID-19. Due to the observational nature of our data, caution is warranted regarding causal interpretation. Our results contribute to the protection of vulnerable populations and may be used for targeting further pharmaceutical interventions.

Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting

“…While both MOV and NMV-r have been shown to be effective in high-risk patients, there is limited evidence in patients with chronic respiratory diseases, which, including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis, are at particularly increased risks of adverse COVID-19 outcomes [ 9 , 10 , 11 , 12 , 13 , 14 ]. Asthma was reported as a risk factor for severe COVID-19 infection with respiratory and systemic complications [ 9 ] and mortality [ 15 ].…”

A Meta-Analysis on the Association between Peptic Ulcer Disease and COVID-19 Severity

“…Further, 390 duplicate articles were excluded; 156 articles were excluded after reading the titles and abstracts, and 38 articles were excluded after scanning the full texts. At last, a total of 15 eligible studies [ 44 , 45 , 46 , 47 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 ] consisting of 4,533,426 patients with COVID-19 were included in this meta-analysis according to the inclusion and exclusion criteria aforementioned. The flowchart of the study selection is illustrated in Figure 1 .…”

The second wave of COVID-19 wreaked havoc: A look at clinical and laboratory parameters of survivors and non-survivors admitted to Intensive Care Unit, a single-centered retrospective study

“…Immunization history should have been taken into consideration in order to assess risk of comorbidities with respect to varying immunization status of patient. [ 21 ]…”